Condition: Arginine Vasopressin Deficiency · Central Diabetes Insipidus · Oxytocin Deficiency · Sponsor: University Hospital, Basel, Switzerland
The study aims to investigate whether intranasal oxytocin (OXT) improves sexual well-being in patients with Arginine Vasopressin Deficiency (AVP-D). The trial consists of two parts: Part A assesses the effect of OXT on sexual well-being and intimacy over a 7-day treatment period in participants in a stable partnership. Part B assesses the effect of a single dose OXT on sexual arousal, fear and empathy in a clinical setting and is designed for single participants and those in partnerships.
This description comes directly from the study's public registry record.
Mirjam Christ-Crain, Prof. MD · +41 61 328 70 80 · mirjam.christ-crain@usb.ch
Cemile Bathelt · +41 61 556 54 07 · cemile.bathelt@usb.ch
Always discuss trial participation with your own doctor first.
| University Hospital Basel | Basel, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06808516